BioMarin Secures 20% Royalty on Ascendis' Yuviwel in Global Patent Settlement
BMRN sits 31% above its 52-week low of $49.259.
Summary
BioMarin resolved all patent litigation with Ascendis Pharma, securing a 20% royalty on U.S. net sales of Yuviwel and 18% in the EU, Brazil, and South Korea through May 2030, retroactive to first commercial sale. This follows BioMarin's strong Q2 and recent Alesta acquisition, adding a recurring high-margin revenue stream from a competing achondroplasia therapy. The settlement removes legal overhang and validates BioMarin's CNP patent estate, potentially boosting earnings visibility. Watch for Ascendis' Yuviwel sales trajectory and any impact on VOXZOGO market share.
At the time of this announcement, BMRN was trading at $64.67 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.5B. The 52-week trading range was $49.26 to $70.98. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: PR Newswire.